Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | HTR2A | P28223 | 5/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | HTR2B | P41595 | 5/20 | 0.53 |
| ▸ | DRD2 | P14416 | 4/20 | 0.53 |
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828313 | 0.85 | ACHE (0.54) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL1911332 | 0.84 | LTA4H (0.60) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL13634431 | 0.84 | LTA4H (0.60) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL13024536 | 0.84 | LTA4H (0.60) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL6828933 | 0.82 | ACHE (0.51) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL3817982 | 0.81 | OPRM1 (0.59) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL1220330 | 0.81 | OPRM1 (0.59) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7498815 | 0.81 | CHRM4 (0.55) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL7498825 | 0.81 | CHRM4 (0.55) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL26618028 | 0.81 | SIGMAR1 (0.57) | SIGMAR1HTR2AHTR2CHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | SIGMAR1 194/4885HTR2A 236/4885HTR2C 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.